Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aventis Insuman

Executive Summary

No FDA communication intended for another company regarding recombinant insulin manufacturing changes was ever received by Aventis, the firm asserts in response to a March 6 story in "The Pink Sheet" (p. 18). The story reported that Aventis had made manufacturing changes for its Insuman Infusat product as a result of FDA's observations. In addition, a semi-synthetic insulin pump product of Aventis, which also goes under the name of Insuman in some European countries, and not the recombinant product, was the subject of leakage problems in Europe. The European Medicines Evaluation Agency said Feb. 14 that the recombinant Insuman Infusat cartridge system carries the same risk for leaks, although no cases have been reported. The semi-synthetic insulin product was approved through the decentralized EU procedure and the recombinant product was cleared through the EMEA centralized procedure
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS035781

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel